| Compound | Semax + Selank |
|---|---|
| Category | Vendor blend (neuropeptides) |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Semax + Selank is catalogued here as a vendor blend (neuropeptides) and graded at the "Minimal evidence" evidence tier. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A vendor combination of two regionally registered Russian neuropeptides. No published study has tested the pair together.
Mechanism of Action
The stated rationale stacks putative neurotrophic (Semax) and anxiolytic (Selank) actions; interaction data do not exist.
Research and Evidence
No combination trials of any quality exist.
Safety and Side Effects
Unverified composition; unknown interaction profile.
Frequently Asked Questions
What is the evidence tier of Semax + Selank?
Semax + Selank is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Semax + Selank an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Semax + Selank?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — no combination trials registered. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.